CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MorphoSys AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MorphoSys AG
Semmelweisstr. 7
Phone: +49 89899270p:+49 89899270 PLANEGG, 82152  Germany Ticker: MORMOR

Business Summary
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Supervisory Board MarcCluzel 69 5/17/2018 5/31/2012
Chairman of the Management Board, Chief Executive Officer Jean-PaulKress 59 9/1/2019 9/1/2019
Independent Deputy Chairman Member of the Supervisory Board George S.Golumbeski 67 1/1/2020 5/17/2018
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Sloning BioTechnology GmbH Zeppelinstrasse 4 Puchheim Germany
Constellation Pharmaceuticals Inc. 215 First Street Cambridge MA United States

Business Names
Business Name
0NDV
0QBV
Constellation Pharmaceuticals Inc
10 additional Business Names available in full report.

General Information
Number of Employees: 524 (As of 12/31/2023)
Outstanding Shares: 37,613,956 (As of 2/29/2024)
Shareholders: 14,206
Stock Exchange: ETR
Fax Number: +49 8989927222


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024